3D Printed Pharmaceutical Tablets: University of Greenwich Case Study

This case study covers why filament printing did not fit, how SLS solved the powder-handling problem, and what the project means for Australian pharmaceutical research today.

How a UK university produces 3D printed pharmaceutical tablets with SLS

The Centre for Innovation and Process Engineering Research, known as CIPER, sits inside the University of Greenwich. The centre has a worldwide reputation for applying 3D printing to pharmaceutical dosage forms and medical devices. Funding has come from industry partners and from EU Research Programs like INTERREG 2 Seas. The Sinterit Lisa was operational at CIPER within one month of purchase in 2020.

A 3D printed pharmaceutical tablet is a drug-loaded dosage form built layer by layer from a polymer powder. Compression manufacturing builds tablets from a single bulk blend. SLS builds them from selectively sintered powder. The SLS route lets scientists tune drug release profiles, mix multiple drug strengths in one production batch, and produce geometries compression tooling cannot achieve.

Why traditional pharmaceutical manufacturing limits personalised dosage

Conventional tablet production uses compression and coating. Material flexibility is limited. Complex internal geometries are hard to achieve. Mixing multiple drug strengths in a single production batch is impractical. Filament-based 3D printing has the same problem. Most pharmaceutical-grade polymers are not sold as printable filaments.

CIPER needed a printer to accept extruded or granulated powders loaded with drug substances directly. The system also had to handle pharmaceutical-grade polymers, large drug payloads, and complex tablet geometries.

How SLS with Hot Melt Extrusion enables 3D printed pharmaceutical tablets

CIPER bought a Sinterit Lisa SLS system in 2020 to produce 3D printed pharmaceutical tablets. A Hot Melt Extrusion step engineered SLS-printable powders from drug-loaded polymers. The Sinterit Lisa then sintered those powders into 3D printed pharmaceutical tablets with immediate, controlled, and sustained-release profiles.

A few features made the difference for pharmaceutical work:

• Open-parameter powder control: important when working with expensive drug substances.

• Process control over environment and bed temperature: critical for thermally sensitive active ingredients.

• Same-batch dosing variation: different drug strengths printed in a single build, supporting personalised dosage forms.

• Post-processing equipment: produces tablets free of unbound powder, ready for downstream handling.

• No filament dependency: the workflow accepts any thermally stable drug substance, not only polymers sold as filament.

The system is cost-effective for pharmaceutical R&D. It reduces processing steps. It supports batch-to-batch production of multiple tablet designs in a single run.

What this means for Australian universities and pharmaceutical research

CIPER bought a Sinterit Lisa when it was the right printer for the job. Sinterit has since superseded the original Lisa range with the Sinterit Lisa X. The Lisa X is the current Sinterit flagship and the printer Australian pharmaceutical research labs should evaluate today. It delivers a 13 litre build volume of 130 by 180 by 330 mm, a 30 W diode laser around six times faster than the Lisa PRO, layer heights from 75 to 175 microns, and an open-parameter mode supporting custom drug-loaded polymer development.

Australian pharmacy schools, biomedical engineering departments, and drug-delivery research labs should mirror the CIPER workflow for 3D printed pharmaceutical tablets. Start with a Sinterit Lisa X and Sinterit PA-12 Industrial powder as the baseline. Layer in pharmaceutical-grade polymers engineered via Hot Melt Extrusion for the active research. The Sinterit Suzy is the compact alternative for smaller research budgets or single-investigator labs.

For broader context on SLS 3D printing in medical and university research beyond 3D printed pharmaceutical tablets, the ECA Medical case study shows the same Sinterit Lisa technology applied to commercial medical device development. The phantom case study from the Institute for Multiscale Simulation shows SLS applied to medical imaging research at a German university. For a deeper technical overview of the process, see what is SLS 3D printing and the Sinterit Lisa X overview.

Frequently asked questions about 3D printed pharmaceutical tablets

• What is a 3D printed pharmaceutical tablet? A 3D printed pharmaceutical tablet is a drug-loaded dosage form built layer by layer from a polymer powder. The SLS route lets formulation scientists tune drug release profiles, combine multiple drug strengths in a single production batch, and produce geometries compression tooling cannot achieve.

• How does SLS 3D printing produce personalised drug dosage? SLS prints inside a powder bed. Each tablet in a build is sintered separately. The same build supports different drug strengths or release profiles in a single run. CIPER at the University of Greenwich uses this property to produce 3D printed pharmaceutical tablets matched to individual patient needs, which is the foundation of personalised medicine work.

• Does the Sinterit Lisa X print pharmaceutical-grade polymers? Yes. The Sinterit Lisa X supports open-parameter powder development. Research labs engineer custom drug-loaded polymers via Hot Melt Extrusion and sinter them on the printer. The original Sinterit Lisa enabled this workflow at CIPER from 2020. The Lisa X extends the same approach with a larger build volume and a faster diode laser.

• Is 3D printed drug tablet manufacturing approved by regulators? 3D printed pharmaceutical tablets are an active area of regulatory development. The first 3D printed drug, Spritam, received FDA approval in 2015. Most current work sits in research and clinical-trial pipelines. The CIPER Sinterit Lisa workflow is geared to formulation R&D and small-batch clinical supply rather than production-scale commercial manufacturing.

• Which Sinterit printer is best for pharmaceutical research? The Sinterit Lisa X is the current Sinterit flagship for pharmaceutical research. It pairs open-parameter powder control with a 13 litre build volume and a 30 W diode laser. The Sinterit Suzy is the compact alternative for smaller research budgets or single-investigator labs.

---

Looking at SLS 3D printing for your pharmaceutical or biomedical research lab? View the Sinterit range at Australian 3D Printers or request a tailored quote.

Leave a comment

Leave a comment

Name*

Email*

Comment*

Send

• Share on:
• WhatsApp
• Deel
• X
• Pin it
• Messenger
• Email

---

Tags

3D Printer 3D Printers CIPER drug/polymer powders Education Learn personalised dosage pharmaceutical 3D printing Prototyping research Sinterit Sinterit Lisa X SLS 3D printing University of Greenwich